Emerging treatment approaches in acute lymphoblastic and acute myeloid leukemias

Xavier Thomas
Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Service d’Hématologie Clinique, Pavillon Marcel Bérard, Bât. 1G, Pierre Bénite, France

Abstract: The choice of treatment approach in acute leukemia depends on well-established prognostic factors. A number of features can predict the outcome of treatment including cytogenetics and an increasing list of molecular features. These are increasingly being used to direct postinduction therapy and support risk-adapted treatments that should achieve optimal results while minimizing nonrelapse mortality. In addition, they are also molecular targets for a new generation of small molecule inhibitors that are in early development and promise to further improve outcomes in the coming decade.

Keywords: acute myeloid leukemia, acute lymphoblastic leukemia, treatment, targeted therapy

Introduction
Acute leukemia remains one of the most challenging adult malignancies, especially with respect to therapy. Despite continuous progress in curing acute leukemia, many challenges remain including relapse among favorable-risk patients, suboptimal cure rates in older adults and dismal treatment outcome among patients who relapse. Improvements have been achieved by intensifying therapy and developing new therapeutic strategies. However, much of the improvements can be attributed to a better understanding and deployment of supportive care to carry patients through the inevitable period of severe pancytopenia caused by effective treatment. The past 10 to 15 years have witnessed substantial progress in the biologic characterization of acute leukemia, leading to the recent development of novel agents and molecular therapeutics that are being incorporated into treatment regimens.

Epidemiology and pathophysiology
Acute myeloid leukemia
Acute myeloid leukemia (AML) is a malignancy that is characterized by infiltration of bone marrow (BM) by abnormal hematopoietic progenitors that disrupt normal production of erythroid, myeloid, and/or megakaryocytic cell lines. AML is a relatively rare disease with a median age of presentation in the late 60s. In younger patients, incidence of AML is two to three per 100,000, which rises to 13 to 15 per 100,000 in the seventh and eighth decade. The French-American-British (FAB) classification, which recognized eight subtypes of AML, was based strictly on morphology and cytochemistry, whereas the current World Health Organization (WHO) classification, which also incorporates cytogenetics and disease history, classify AML
into the following groups: (i) AML with recurrent cytogenetic abnormalities; (ii) AML with multilineage dysplasia; (iii) AML and myelodysplastic syndrome (MDS) therapy related; (iv) and AML not otherwise categorized. The outcome of treatment for adults with AML depends not only on the age and the type of postremission therapy, but also on biologic characteristics of the disease. Cytogenetics remains the most important prognostic factor. Three cytogenetic groups can be distinguished: a favorable group with core binding factor (CBF) leukemias \([\text{inv}(16), t(16;16), \text{or} \ t(8;21)]\) and acute promyelocytic leukemia (APL) \([t(15;17)];\) an unfavorable group with monosomies or partial deletions of chromosome 5 and/or 7, 11q23 abnormalities, or with abnormalities involving \(\geq3\) chromosomes (complex abnormalities); and the remaining patients whose prognosis is intermediate. Long-term event-free survival in CBF leukemias is 50%–70%, while that of intermediate-risk cytogenetics is 30%–50% and that of unfavorable cytogenetics is approximately 10%–15%. Research in defining prognostic factors has started to examine molecular markers, beginning with the \(\alpha\) subunit of cytoplasmic gene, and \(\alpha\) the gene for the apoptosis regulators B-cell lymphoma protein, \(\alpha\) and \(\alpha\) nuclearophosmin; especially in the form of internal tandem duplication (ITD); and \(\alpha\) fms-like tyrosine kinase 3 gene, \(\alpha\) nucleus of patients whose prognosis is intermediate. Long-term event-free survival in CBF leukemias is 50%–70%, while that of intermediate-risk cytogenetics is 30%–50% and that of unfavorable cytogenetics is approximately 10%–15%. Research in defining prognostic factors has started to examine molecular markers, beginning with the \(\alpha\) subunit of cytoplasmic gene, \(\alpha\) the genes for the apoptosis regulators B-cell lymphoma protein, \(\alpha\) and BCL2-associated X protein, \(\alpha\) and \(\alpha\) nuclearophosmin; especially in the form of internal tandem duplication (ITD); and \(\alpha\) fms-like tyrosine kinase 3 gene, \(\alpha\) nucleus of patients whose prognosis is intermediate. Long-term event-free survival in CBF leukemias is 50%–70%, while that of intermediate-risk cytogenetics is 30%–50% and that of unfavorable cytogenetics is approximately 10%–15%.

### Acute lymphoblastic leukemia

Acute lymphoblastic leukemia (ALL), a clonal expansion of hematopoietic blasts, is a highly heterogeneous disease comprising many entities for which distinct treatment strategies are pursued. ALL is a malignant neoplasm of the lymphocyte precursor cells. The age-adjusted overall incidence of ALL is 1.5 per 100,000 population peaking between ages 2 and 5 years and again after 50 years. Most reports about etiologic associations remain isolated and conflicting. ALL is characterized by aberrations in proliferation and differentiation of lymphoblasts, leading to failure of normal immune response and decreased production of normal hematopoiesis responsible for anemia, thrombocytopenia, and neutropenia. Both T-cell and B-cell precursors can be involved in the malignant process. ALL is a heterogeneous disease with distinct morphologic, cytogenetics, and molecular groupings, some of which have important clinical implications. The FAB classification, which recognized three subtypes of ALL, was based strictly on morphology and cytochemistry, whereas the current WHO classification incorporates immunophenotyping and cytogenetics-molecular abnormalities that provide prognostic information, markers for therapy, targets for drug development, and pathobiologic insights (Table 1). The ambiguous expression of myeloid markers with lymphoid markers is common, especially in ALL with translocations \(t(9;22), t(4;11),\) and \(t(12;21).\) Although prognostic significance of myeloid antigens is controversial, it can help to distinguish leukemic cells from hematogones and in monitoring patients for minimal residual disease (MRD). Several molecular markers have been identified as key players in leukemogenesis. Activating mutations of \(\text{NOTCH-1},\) a transmembrane receptor-encoding gene that regulates

#### Table 1 Cytogenetic and molecular abnormalities in adult ALL

<table>
<thead>
<tr>
<th>Karyotype and Molecular marker</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>del(11)(q22)</td>
<td>ATM</td>
</tr>
<tr>
<td>t(9;22)(q34;q11)</td>
<td>BCR-ABL1</td>
</tr>
<tr>
<td>t(14;11)(q13)</td>
<td>TCRα, TCRδ</td>
</tr>
<tr>
<td>del(9)(p21-22)</td>
<td>CDKN2A, CDKN2B</td>
</tr>
<tr>
<td>t(11q23;q11)</td>
<td>TAL-1</td>
</tr>
<tr>
<td>+8</td>
<td></td>
</tr>
<tr>
<td>del(7p)</td>
<td></td>
</tr>
<tr>
<td>+18</td>
<td></td>
</tr>
<tr>
<td>+18</td>
<td></td>
</tr>
<tr>
<td>del(11)(q23)</td>
<td>MLL</td>
</tr>
<tr>
<td>del(11)(q22)</td>
<td></td>
</tr>
<tr>
<td>t(8;14), t(8;22) or t(2;8)</td>
<td>c-MYC</td>
</tr>
<tr>
<td>t(14q32)</td>
<td>IGH, BCL11B</td>
</tr>
<tr>
<td>del(13)(q14)</td>
<td>mIR15/mIR16</td>
</tr>
<tr>
<td>t(1;19) or t(17;19)</td>
<td>TCF3-PBX1, E2A-HLF</td>
</tr>
<tr>
<td>del(5)(q35)</td>
<td>HOX11L2</td>
</tr>
<tr>
<td>t(5;14)(q35;q32)</td>
<td>HOX11L2</td>
</tr>
<tr>
<td>del(9)(q32)</td>
<td>TAL-2</td>
</tr>
<tr>
<td>del(12p) or t(12p)</td>
<td>ETV6-RUNX1</td>
</tr>
<tr>
<td>Extra chromosome 9q</td>
<td>NUP214/ABL</td>
</tr>
</tbody>
</table>
normal T-cell development, have been detected in the majority of T-cell ALLs. Loss of SMAD family member 3 (Smad3) has been identified in samples from T-lineage ALL. Epigenetic changes, including hypermethylation of tumor-suppressor genes or microRNA genes and hypomethylation of oncogenes have been identified in 80% of patients. ALL represents less than 1% of adult cancers, while it represents 25% of all childhood cancers. Principles of chemotherapy for adult ALL are therefore based on those initially developed for children.

**Established and emerging therapy options**

**Acute myeloid leukemia**

**Established treatments**

**Standard treatment of AML**

The pursuit of the best chemotherapy regimen for AML continues in an attempt to improve complete remission (CR) proportions and long-term disease-free (DFS) and overall survival (OS). The modern era of treatment began in the 1970s with the introduction of anthracyclines and cytarabine as critical components that provide synergistic activity in induction regimens. In the 1980s, a schedule of daunorubicin at a dose of 45 mg/m² intravenously for 3 days plus cytarabine at a dose of 100 mg/m² intravenously for 7 days (‘3 + 7’ schedule) appeared more effective. This corresponds to the standard against which most new regimens were tested. Continuous infusion of cytarabine was more effective than single daily intravenous infusions. Daunorubicin given at 45 mg/m² was more effective than 30 mg/m², while cytarabine was equally effective at 100 mg/m² or 200 mg/m². 6-thioguanine did not improve results when added to daunorubicin and cytarabine.

Although not demonstrating an improved remission rate, addition of etoposide to a standard ‘3 + 7’ schedule showed improved DFS. Several randomized trials showed that idarubicin, aclarubicin, and amsacrine may be superior to daunorubicin in younger adults, while mitoxantrone is at least as effective as daunorubicin. However, these agents have been compared with daunorubicin at a dose of 45 mg/m² and it is not clear that any observed improvement represents an inherent biological advantage of a particular drug rather than biological dose equivalence. Increasing the intensity of induction may be effective because achieving CR is the first condition for prolonged DFS and intensified induction therapy may affect the long-term survival even without an apparent effect on the initial response rate. The focus of research in the 1990s has therefore been on intensifying induction therapy. Several schedules have been able to deliver remission rates of 75%–80% in patients aged >60 years old. Dose escalation strategies include more days of: regularly dosed cytarabine and anthracyclines, high-dose cytarabine, or higher dose of daunorubicin, or more intensive schedules such as timed-sequential chemotherapy or double induction regimens. Overall, clinical trials with escalating intensity of therapy demonstrated no consistent advantage for remission induction, but did improve DFS. Recently, a meta-analysis of several published randomized trials demonstrated a significant benefit for using high-dose cytarabine in induction in patients younger than 60 years.

A variety of postremission approaches have been explored. Such strategies include intensive consolidation therapy, low-dose maintenance therapy, or autologous or allogeneic stem cell transplantation (SCT). Balancing risks and benefits of different treatment approaches in accordance with the individual prognostic profile of patients is the current basic principle of treatment in AML. A number of studies have suggested that increasing the intensity of postremission therapy with doses of drugs higher than that used in standard maintenance regimens improves treatment outcome. Several studies have prospectively evaluated the role of intensive postremission consolidation with high-dose cytarabine.

Four courses of cytarabine at one of the three doses were tested: 100 mg/m²/day by continuous intravenous infusion for 5 days, 400 mg/m²/day by continuous intravenous infusion for 5 days, and 3000 mg/m² as a 3-hour intravenous infusion twice daily on days 1, 3, and 5. DFS was 21% in the 100 mg group, 25% in the 400 mg group, and 39% in the 3000 mg group. The difference was statistically significant in patients younger than 60 years. The results were most significant in patients with favorable cytogenetics. The high- and intermediate-dose regimens were of equivalent benefit in patients with intermediate-risk cytogenetics. There was no evidence that any of the three strategies were superior in patients with unfavorable cytogenetics. However, the use of high-dose cytarabine remains too toxic in the elderly. Higher doses of cytarabine (18 g/m²/cycle) have therefore been standard for consolidation therapy in younger patients since the early 1990s and are associated with a survival benefit in CBF and intermediate-risk AMLs. This high-dose cytarabine consolidation approach has also been recommended for patients with mutations in NPM1 and CEBPα in the absence of FLT3-ITD mutations. The number of courses of high-dose cytarabine required for optimal postremission therapy remains uncertain. Given the evidence that intensifying postremission therapy improves the outcome of patients, studies have compared the relative benefits of intensive...
consolidation with high-dose cytarabine, autologous SCT, and allogeneic SCT. Several observations emerge from these studies: (i) due to the particular designs of these studies, a substantial proportion of patients randomized to autologous SCT failed to complete their assigned treatment; (ii) although allogeneic SCT offers the potential of graft-versus-leukemia (GvL) effect and therefore the lowest risk of relapse, higher treatment-related mortality diminishes the impact of its increased antileukemic potential; (iii) it is likely that the mortality rate associated with both autologous and allogeneic SCT will continue to decrease. Allogeneic SCT is probably still the most effective anti-AML therapy. As the donor pool expands to include more unrelated donors and umbilical cords, and as treatment-associated morbidity and mortality rates decline with improvements in human leukocyte antigen (HLA) matching, supportive cares, and management of graft-versus-host disease (GvHD), it is becoming increasingly feasible for more patients with AML to undergo the procedure. All AML patients with complex cytogenetics or monosomal karyotype should be considered for allogeneic SCT. Patients with FLT3-mutated AML and those with normal cytogenetics and FLT3, CEBPa, and NPM1 unmutilated disease may be considered for allogeneic SCT. Reduced-intensity conditioning (RIC) regimens for allogeneic SCT that relies on the generation of a GvL effect to eradicate leukemia have been developed for older adults with AML. The treatment-related mortality (TRM) is approximately 30% and outcomes among patients undergoing matched sibling donor or matched unrelated donor SCT do not appear to differ. It is not known which patients are most likely to benefit and whether achieving CR after induction chemotherapy alone represents sufficient reduction in the leukemia burden to realize the maximal potential of transplantation. The role of postconsolidation maintenance therapy is not clearly defined. Although not generally considered in the treatment of AML, monthly maintenance therapy has shown a potential benefit when analyzing long-term follow-up data.

Treatment of acute promyelocytic leukemia

Several developments over the past 30 years have made acute promyelocytic leukemia (APL) the most curable of all types of AML. Addition of all-trans retinoic acid (ATRA) to chemotherapy is of clear benefit and represents the current standard approach for newly diagnosed APL. ATRA should be used together with anthracyclines during induction and probably during postremission therapy. Patients generally receive two cycles of consolidation. Anthracyclines are particularly effective in APL and have been proposed as monochemotherapy in combination with ATRA in lower risk APL. The development of a polymerase chain reaction (PCR) test to detect the fusion gene PML/RARA product of the characteristic t(15;17) provides a sensitive and highly specific means to monitor minimal residual disease. The achievement of molecular remission rates of 90%–99% in patients receiving at least two further cycles of anthracycline-based chemotherapy after induction has led to the adoption of this strategy as the standard for consolidation. In spite of the benefit provided by ATRA-based maintenance therapy in randomized studies, the systematic use of postconsolidation therapy is still a controversial matter in patients achieving molecular remission at the end of consolidation. The benefit provided by ATRA-based maintenance therapy in two randomized studies has been questioned in a large study by Italian researchers. Two other randomized trials exploring the role of maintenance are ongoing: one comparing arsenic trioxide alone versus arsenic trioxide plus mercaptopurine and methotrexate, and one comparing ATRA versus the synthetic retinoid tamibarotene. Arsenic trioxide is currently regarded as the best option in the context of relapsing APL. Arsenic trioxide produces complete remission rates of 80% in relapsed APL and may be more effective than ATRA. Its role in induction and/or in postinduction therapy as first-line therapy in newly diagnosed APL is also currently being explored. In second-line therapy, the choice of transplant modality is mainly based on PCR status achieved after reinduction. After rescue with arsenic trioxide, an additional course of arsenic trioxide and ATRA as consolidation is recommended. This approach should be followed by molecular assessment of response by PCR of PML/RARA. Patients with persistent PCR positivity must be, when feasible, allocated to allogeneic SCT. Allogeneic SCT can also be recommended for patients with short first complete response, regardless of the molecular status after salvage therapy. For patients with prolonged first response (>1 year) who are in second complete molecular response, distinct strategies are available and include SCT, additional cycles of arsenic trioxide, and/or chemotherapy with or without ATRA. In patients for whom both options are feasible, autologous or allogeneic SCT are potentially curative options.

Emerging therapy options

Despite considerable progress in the treatment of AML in recent decades, the prognosis of the majority of patients remains guarded. Only about 40% of younger adults and
less than 10% of older patients will experience long-term survival. Current research is focusing on the identification of prognostic indicators allowing treatment stratification, the determination of new cellular targets leading to novel specific inhibitors, and the design of new therapeutic strategies combining those new agents with traditional chemotherapy. Although few new drugs have been approved for AML over the past 20 years, new strategies and new agents with diverse putative mechanisms of action are emerging and are currently entering clinical trials.

**Gemtuzumab ozogamicin**

Gemtuzumab ozogamicin is an immunoconjugate of an anti-CD33 antibody linked to a potent cytotoxic agent, calicheamicin. The results with gemtuzumab as a single agent for older adults as initial induction therapy have been modestly encouraging. The addition of gemtuzumab ozogamicin to induction therapy or as postconsolidation therapy in the Southwest Oncology Group (SWOG) trial, S0106, was associated with a significantly higher risk of fatal induction adverse events that led to the withdrawal of the drug from the US market. However, recent randomized studies have suggested that it may be associated with a higher remission rate when administered with intensive chemotherapy. Patients with favorable-risk cytogenetics appeared to derive a significant benefit from the addition of gemtuzumab. An OS benefit has recently been shown from a French randomized trial.

**New purine analogs**

New purine analogs such as clofarabine and fludarabine exert synergistic activity with cytarabine to increase intracellular levels of the toxic metabolite cytarabine triphosphate. Fludarabine is a DNA synthesis inhibitor. Once activated, it inhibits DNA polymerase, but also ribonucleotide reductase, DNA primase, and DNA ligase I, resulting in DNA deletions and mutations. Clofarabine is an intravenous second-generation purine analog intentionally designed to combine the favorable properties of fludarabine and cladribine. It is active in both dividing and nondividing cells and exerts an antiproliferative effect in two important ways by both inhibiting ribonucleotide reductase and incorporating directly into DNA. In a Phase II study in patients with adverse features, clofarabine showed an overall response rate of 46% with a CR rate of 38%. Combined with other agents, such as low-dose cytarabine, a higher CR rate was reported with an improvement in terms of OS and DFS.

**FLT3 inhibitors**

The fms-like tyrosine kinase-3 (FLT3) is a receptor tyrosine kinase playing an important role in the differentiation and proliferation of hematopoietic progenitor cells. Mutations occur in about one third of patients with AML and are associated with shorter survival. A number of inhibitors of FLT3 kinase are currently under evaluation in AML. Midostaurin has demonstrated activity in mutated patients. Sorafenib, a multikinase inhibitor, has shown potent activity both as a single agent and in combination with cytotoxic agents. More recently, AC220, a highly specific second generation inhibitor, has been evaluated in a promising Phase I study showing approximately 50% of response in relapsing patients.

**Hypomethylating agents**

The potential reversibility of epigenetic changes that contribute to the development of AML has suggested that it may be possible to reestablish normal patterns of gene expression by means of chromatin-remodeling agents. Hypermethylation of promotor regions of tumor suppressor genes has been associated with an adverse outcome in both high-risk myelodysplastic syndrome and AML. Azacitidine and 5-aza-2′-deoxycytidine can induce gene and global hypomethylation in vivo, allowing normal gene transcription to resume. Because of the possibility that these agents work via other mechanisms, it is also adequate to refer to them as DNA methyltransferase inhibitors based on the enzyme they inhibit. In a Phase II study involving 55 patients (median age: 74 years) treated with decitabine at a dose of 20 mg/m² daily for 5 days, an overall response rate of 25% was reported with a median survival duration of 7.7 months. In another study, decitabine was administered at a daily dose of 20 mg/m² for 10 days to 53 patients older than 60 years. The overall response rate was 64% including 47% CR and mortality during the first 8 weeks was only 15%. More recently, results from a large Phase III trial involving 485 newly diagnosed older AML patients showed a significant survival advantage (median survival: 7.7 months versus 5 months; *P = 0.03*) and higher response rates for decitabine when compared to accepted standard therapies, without major differences in terms of safety.

On the AZA-001 trial, 113 patients exhibiting bone marrow blast percentages between 20% and 29% are classified as AML according to the WHO criteria. Fifty-five patients were randomized in the azacitidine arm, while 58 received conventional care regimens. Although CR rates were similar, azacitidine was better tolerated with...
fewer severe infections and fewer days in hospitalization. The 2-year survival was better in the azacytidine arm. However, this still remains to be proven for patients with higher blasts percentage.

Combining decitabine or azacytidine with other epigenetic modulators has been evaluated. Histone deacetylase inhibitors re-establish gene transcription either alone or following the administration of a methyltransferase inhibitor. Suberoylanilide hydroxamic acid (SAHA), valproic acid, depsipeptide, and MS-275 are examples of such novel agents.

Other new agents
Cloretazine, an alkylating agent, has been evaluated in combination with cytarabine in a randomized study. Response rate was higher for the combination, but mortality was also higher with no difference among the two groups in terms of OS and DFS. The proteosome inhibitor bortezomib appears to have single-agent activity in acute leukemia and has synergistic activity with histone deacetylase inhibitors. Other new agents under investigation in AML include farnesyltransferase inhibitors (tipifarnib), antiangiogenesis agents (bevacizumab), aminopetidase inhibitors (tosedostat), apoptosis inhibitors (Bcl-2 antisense oligonucleotide), a liposome encapsulated 5:1 molar combination of cytarabine and daunorubicin (CPX-351), and a quinolone derivative that intercalates DNA (voreloxin), and number of other agents that target various aspects of the leukemia cell machinery.

New therapeutic strategies
Many trials have evaluated myeloid growth factors in the supportive care setting in AML. In spite of evidence that neutropenia can be curtailed, there was no consistent evidence of improvement in disease outcome. In contrast, encouraging data have been reported recently regarding the use of growth factors in priming leukemia cells and thereby increasing sensitivity to chemotherapy. However, this remains a controversial issue for which studies showed inconsistent results.

Acute lymphoblastic leukemia
Established treatments
Because of specific treatments available for unique ALL subtypes, Philadelphia chromosome-positive (Ph+) ALL might be differentiated from Ph-negative ALL, and mature Burkitt B-lymphoma/leukemia from B- and T-cell precursor ALL.

Standard treatment of ALL
Most therapeutic advances in adult ALL have arisen from successful adaptation of ALL treatment in children. Results of main standard treatment programs for adult ALL are indicated in Table 2. Historically, induction therapy for adult ALL has been built around a “backbone” of vincristine and prednisone. The combination of vincristine and prednisone alone produces CR rates of approximately 35% to 65% but median remission duration of only 3 to 7 months. Intensifying induction therapy by adding an anthracycline was first shown in a randomized Cancer and Leukemia Group B (CALGB) trial to significantly increase the likelihood of achieving a CR from about 50% to 78%. These results were then confirmed by other studies. The anthracyclines used include doxorubicin, daunorubicin, and more recently idarubicin and rubidazone. Daunorubicin has been the most extensively studied because of its availability for the longest period of time, its activity, and its lower gastrointestinal mucosal toxicity. The optimal schedule for anthracycline administration is controversial. The two most commonly schedules are once weekly or daily for 3 days for each course. According to the pediatric experience, the administration over 2 or 3 days achieves a faster antileukemic effect through greater myelosuppression. Although there are no randomized studies addressing further intensification of induction therapy, almost all modern treatment regimens add L-asparaginase or cyclophosphamide to induction therapy. Asparaginase does not affect the CR rate, but probably improves leukemia-free survival and if not used during induction therapy, it is often included as part of the consolidation treatment. However, the addition of L-asparaginase to vincristine and prednisolone in pediatric studies has led to improved CR rates in relapsed ALL patients. Cyclophosphamide also does not raise the overall CR rate, but possibly improves the remission quality. Accordingly, standard induction regimens can be labeled as four-drug (vincristine, prednisone, anthracycline, and cyclophosphamide or L-asparaginase) or five-drug (vincristine, prednisone, anthracycline, cyclophosphamide, and L-asparaginase) regimens. No data favor one of these induction regimens over another. A pediatric study showed that the sum of the percentages of three induction drugs (vincristine, L-asparaginase and anthracyclines) delivered were critical in predicting relapse, supporting the concept that the dose intensity of the drugs delivered in induction is important for long-term prognosis. In an effort to improve upon the outcome, modifications of these standard treatments have been proposed by the addition of known chemotherapy drugs, intensification of chemotherapy doses,
Drugs. High-dose cytosine arabinoside has been introduced to be related to the concurrent use of other cytotoxic drugs does not increase CR rates or incorporation of novel ‘targeted’ drugs. Although, the addition of other cytotoxic drugs does not increase CR rates substantially, the highest remission rates have been achieved with multidrug induction regimens. Modifications in the chemotherapeutic schedule could include the type and place of corticosteroids, the addition of other drugs during induction, or an intensification of anthracycline doses. Response at a 7-day pretreatment with prednisolone as measured by a cautious cell reduction phase is recommended for patients with a large leukemic cell burden and/or a high leukocyte count at diagnosis. Dexamethasone has been shown more rapid reduction of leukemia cells. The rapidity of CR rate of 91%. Methotrexate at a dose of 6 g/m2 yields cytotoxic levels in the cerebrospinal fluid. Several studies have investigated the efficacy of high-dose methotrexate as induction treatment in combination with other chemotherapeutic agents in adult ALL. Anthracyclines induce more rapid reduction of leukemia cells. The rapidity of CR

<table>
<thead>
<tr>
<th>Reference</th>
<th>Pts</th>
<th>Age* (range)</th>
<th>CR</th>
<th>DFS</th>
<th>OS</th>
<th>Allogeneic SCT strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gaynor et al</td>
<td>198</td>
<td>(16–83)</td>
<td>85%</td>
<td>3 years</td>
<td>50%</td>
<td>Ph* with donor</td>
</tr>
<tr>
<td>Petersdorf et al</td>
<td>353</td>
<td>(15–84)</td>
<td>62%</td>
<td>5 years</td>
<td>8 years</td>
<td>–</td>
</tr>
<tr>
<td>Bassan et al</td>
<td>121</td>
<td>(15–74)</td>
<td>84%</td>
<td>48%</td>
<td>49%</td>
<td>HR with donor</td>
</tr>
<tr>
<td>Takeuchi et al</td>
<td>263</td>
<td>(15–59)</td>
<td>78%</td>
<td>3 years</td>
<td>3 years</td>
<td>–</td>
</tr>
<tr>
<td>(JALSG 93)</td>
<td>153</td>
<td>(16–82)</td>
<td>86%</td>
<td>30%</td>
<td>28%</td>
<td>HR with donor</td>
</tr>
<tr>
<td>(Sweden)</td>
<td>767</td>
<td>(12–60)</td>
<td>92%</td>
<td>9 years</td>
<td>9 years</td>
<td>–</td>
</tr>
<tr>
<td>Annino et al</td>
<td>288</td>
<td>(15–92)</td>
<td>38%</td>
<td>38%</td>
<td>38%</td>
<td>Ph* with donor</td>
</tr>
<tr>
<td>(GIMEMA 02/88)</td>
<td>340</td>
<td>(14–79)</td>
<td>74%</td>
<td>5 years</td>
<td>5 years</td>
<td>–</td>
</tr>
<tr>
<td>Kantarjian et al</td>
<td>922</td>
<td>(15–55)</td>
<td>84%</td>
<td>6 years</td>
<td>6 years</td>
<td>–</td>
</tr>
<tr>
<td>(MDACC)</td>
<td>198</td>
<td>(15–59)</td>
<td>86%</td>
<td>3 years</td>
<td>3 years</td>
<td>–</td>
</tr>
<tr>
<td>Labar et al</td>
<td>713</td>
<td>(15–50)</td>
<td>34%</td>
<td>5 years</td>
<td>5 years</td>
<td>–</td>
</tr>
<tr>
<td>(EORTC ALL3)</td>
<td>222</td>
<td>(15–55)</td>
<td>35%</td>
<td>5 years</td>
<td>5 years</td>
<td>–</td>
</tr>
<tr>
<td>Thomas et al</td>
<td>1646</td>
<td>(15–64)</td>
<td>90%</td>
<td>39%</td>
<td>39%</td>
<td>All pts with donor</td>
</tr>
<tr>
<td>(LALA 94)</td>
<td>433</td>
<td>(15–92)</td>
<td>90%</td>
<td>5 years</td>
<td>5 years</td>
<td>–</td>
</tr>
<tr>
<td>(GOELAL 02)</td>
<td>922</td>
<td>(15–57)</td>
<td>84%</td>
<td>5 years</td>
<td>5 years</td>
<td>–</td>
</tr>
<tr>
<td>Ribera et al</td>
<td>198</td>
<td>(16–83)</td>
<td>92%</td>
<td>9 years</td>
<td>9 years</td>
<td>–</td>
</tr>
<tr>
<td>(PETHEMA ALL93)</td>
<td>713</td>
<td>(15–59)</td>
<td>86%</td>
<td>38%</td>
<td>38%</td>
<td>Ph* with donor</td>
</tr>
<tr>
<td>Gokbuget et al</td>
<td>222</td>
<td>(15–92)</td>
<td>74%</td>
<td>36%</td>
<td>36%</td>
<td>All pts with donor</td>
</tr>
<tr>
<td>(GMALL 07)</td>
<td>198</td>
<td>(15–59)</td>
<td>86%</td>
<td>5 years</td>
<td>5 years</td>
<td>–</td>
</tr>
<tr>
<td>Goldstone et al</td>
<td>713</td>
<td>(15–50)</td>
<td>34%</td>
<td>5 years</td>
<td>5 years</td>
<td>–</td>
</tr>
<tr>
<td>(MRC/ECOG)</td>
<td>433</td>
<td>(15–64)</td>
<td>90%</td>
<td>39%</td>
<td>39%</td>
<td>All pts with donor</td>
</tr>
<tr>
<td>Corneliussen et al</td>
<td>1646</td>
<td>(15–55)</td>
<td>90%</td>
<td>39%</td>
<td>39%</td>
<td>All pts with donor</td>
</tr>
</tbody>
</table>

**Note:** Median.

**Abbreviations:** ALL, acute lymphoblastic leukemia; CALGB, Cancer and Leukemia Group B; CR, complete remission; DFS, disease-free survival; EORTC, European Organisation for Research and Treatment of Cancer; GIMEMA, Gruppo Italiano Malattie Ematologiche dell’Adulto; GMALL, German Multicenter Study Group for Adult ALL; GOELAL, Groupe Ouest-Est des Leucémies Aigues et Maladies du Sang; HOVON, Dutch–Belgium Cooperative Trial Group for Hematology/Oncology; HR, high-risk; JALSG, Japan Adult Leukemia Study Group; LALA, Leucémies Aiguës Lymphoblastiques de l’Adulte; MDACC, MD Anderson Cancer Center; MRC/ECOG, Medical Research Council/Eastern Cooperative Oncology Group; NLG, Northern Italy Leukemia Group; NR, not reported; OS, overall survival; PETHEMA, Programa Espanol de Tratamiento en Hematologia; Ph*, Philadelphia chromosome-positive; Pts, patients; SCT, stem cell transplantation; SWOG, Southwest Oncology Group.
achievement is associated with long-term outcome. The long-term DFS was found to improve when an anthracycline was administered in high doses delivered in a short time.\textsuperscript{120} Early dose intensification of daunorubicin would lead to superior leukemia-free survival.\textsuperscript{121}

The antileukemic potential of allogeneic SCT in adult ALL has been confirmed in several studies. A large prospective Medical Research Council (MRC) UKALL XII/ Eastern Cooperative Oncology Group (ECOG) E2993 trial showed a benefit on a donor versus no donor basis for allogeneic sibling transplanted standard-risk ALL with a 5-year OS of 62\% versus 52\% and a relapse rate of 24\% versus 49\% respectively.\textsuperscript{105} For high-risk ALL patients there was no significant difference concerning OS. However, a meta-analysis of all prospective trials showed a significant benefit for sibling allogeneic SCT in high-risk patients.\textsuperscript{122} In a more recent meta-analysis, allogeneic SCT was superior to autologous SCT or chemotherapy for patients with ALL in first CR.\textsuperscript{123} The survival advantage was of greater statistical significance for patients with standard-risk than for patients with high-risk ALL. This may be explained in part by differences in the definition of high risk versus standard risk. Furthermore, approximately 60\% of adults aged less than 30 years with standard-risk ALL can be cured by chemotherapy, sparing them from the long-term adverse events associated with allogeneic SCT. The recent demonstration of outcome improvements in adolescents and young adults (AYAs) who were treated on pediatric regimens compared to those treated on adult regimens (Table 3)\textsuperscript{124–128} also diminishes the need to refer this patient group for transplantation.

In the absence of siblings, high-risk ALL adult patients are generally considered for alternative donor SCT. Retrospective studies reported promising results with unrelated donors\textsuperscript{129–132} within several studies, OS and relapse rates similar to those observed with a sibling donor.\textsuperscript{129,130,132}

### Table 3 Outcome of treatment in adolescents and young adults (AYAs) with ALL

<table>
<thead>
<tr>
<th>Reference</th>
<th>Type of trial</th>
<th>Age (years)</th>
<th>Patients</th>
<th>CR (5 years)</th>
<th>DFS (5 years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock et al\textsuperscript{124}</td>
<td>Pediatric</td>
<td>16–21</td>
<td>196</td>
<td>96%</td>
<td>64%</td>
</tr>
<tr>
<td>Adult</td>
<td>103</td>
<td></td>
<td>93%</td>
<td>38%</td>
<td></td>
</tr>
<tr>
<td>Boissel et al\textsuperscript{125}</td>
<td>Pediatric</td>
<td>15–20</td>
<td>77</td>
<td>94%</td>
<td>67%</td>
</tr>
<tr>
<td>Adult</td>
<td>100</td>
<td></td>
<td>83%</td>
<td>41%</td>
<td></td>
</tr>
<tr>
<td>DeBont et al\textsuperscript{126}</td>
<td>Pediatric</td>
<td>15–18</td>
<td>47</td>
<td>98%</td>
<td>69%</td>
</tr>
<tr>
<td>Adult</td>
<td>44</td>
<td></td>
<td>91%</td>
<td>34%</td>
<td></td>
</tr>
<tr>
<td>Testi et al\textsuperscript{127}</td>
<td>Pediatric</td>
<td>14–18</td>
<td>150</td>
<td>94%</td>
<td>80%</td>
</tr>
<tr>
<td>Adult</td>
<td>95</td>
<td></td>
<td>89%</td>
<td>71%</td>
<td></td>
</tr>
<tr>
<td>Ramanujachar et al\textsuperscript{128}</td>
<td>Pediatric</td>
<td>15–17</td>
<td>61</td>
<td>98%</td>
<td>65%</td>
</tr>
<tr>
<td>Adult</td>
<td>67</td>
<td></td>
<td>94%</td>
<td>49%</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** CR, Complete remission; DFS, disease-free survival.

TRM was significantly higher with HLA-mismatched donors.\textsuperscript{131} Published studies demonstrated that umbilical cord blood transplantation is an effective treatment alternative for adults with high-risk ALL, lacking a sibling donor or a matched unrelated donor.\textsuperscript{133,134} The limited cell dose of cord blood units can be overcome by the use of double umbilical cord blood units. RIC regimens have been developed over the past decade, with the aim of reducing TRM and making allogeneic SCT feasible in older patients or patients with comorbidities. Small prospective studies in adult ALL patients in first remission demonstrated a 2-year OS at 30\%,\textsuperscript{135,136} Retrospective studies showed globally higher OS rates.\textsuperscript{137,138} An effective GvL effect has been demonstrated.\textsuperscript{139} RIC regimens reduce nonrelapse mortality rate, but with a higher probability of leukemia relapse, inducing similar OS as compared to myeloablative regimens.

Patients who are MDR negative were shown to have a significantly better survival.\textsuperscript{140} Postgraft maintenance remains marginal, but was attempted with some suggested benefit.\textsuperscript{141}

### Treatment of Philadelphia chromosome-positive ALL

The Ph chromosome [t(9;22) and/or BCR-ABL ALL] can be detected in a range of 20\% to 40\% of adults with ALL. Historically, chemotherapy regimens induced CRs in about 70\% of the cases, but most patients relapsed and died of the disease.\textsuperscript{98,101} Only the hyperCVAD chemotherapy from the MD Anderson Cancer Center reported higher CR rate (91\%) with better outcome.\textsuperscript{147} Chemotherapy in elderly Ph+ ALL patients was also associated with a very poor outcome, but (in contrast with younger adults) the presence of Ph chromosome had no impact on the prognosis because of the overall poor outcome of ALL in the elderly.\textsuperscript{142} Following initial studies showing that use of imatinib mesylate as a single agent in Ph+ ALL yielded potential responses but was unlikely to be sufficient for long-term disease control, the efficacy of imatinib was explored as front-line treatment combined with chemotherapy, either concurrently (simultaneous administration) or sequentially (alternating administration). Results of imatinib-based therapy are given in Table 4.\textsuperscript{143–152} In younger adults, imatinib-based regimens, in which imatinib was given at 400 mg to 800 mg/day, showed significant better results in terms of response as well as of survival when compared to historical control patients treated with chemotherapy alone.\textsuperscript{143–145,150} Transplant candidates had a better chance of receiving allogeneic SCT with imatinib-combined regimen.\textsuperscript{144} Alternating and concurrent imatinib-chemotherapy combinations have been compared.\textsuperscript{148} Efficacy analyses based on BCR-ABL transcript levels showed a clear advantage for

---

Historically, chemotherapy regimens induced CRs in about 70\% of the cases, but most patients relapsed and died of the disease.\textsuperscript{98,101} Only the hyperCVAD chemotherapy from the MD Anderson Cancer Center reported higher CR rate (91\%) with better outcome.\textsuperscript{147} Chemotherapy in elderly Ph+ ALL patients was also associated with a very poor outcome, but (in contrast with younger adults) the presence of Ph chromosome had no impact on the prognosis because of the overall poor outcome of ALL in the elderly.\textsuperscript{142} Following initial studies showing that use of imatinib mesylate as a single agent in Ph+ ALL yielded potential responses but was unlikely to be sufficient for long-term disease control, the efficacy of imatinib was explored as front-line treatment combined with chemotherapy, either concurrently (simultaneous administration) or sequentially (alternating administration). Results of imatinib-based therapy are given in Table 4.\textsuperscript{143–152} In younger adults, imatinib-based regimens, in which imatinib was given at 400 mg to 800 mg/day, showed significant better results in terms of response as well as of survival when compared to historical control patients treated with chemotherapy alone.\textsuperscript{143–145,150} Transplant candidates had a better chance of receiving allogeneic SCT with imatinib-combined regimen.\textsuperscript{144} Alternating and concurrent imatinib-chemotherapy combinations have been compared.\textsuperscript{148} Efficacy analyses based on BCR-ABL transcript levels showed a clear advantage for
the simultaneous over the alternating schedule, with 52% of patients achieving PCR negativity (versus 19%). Several approaches using imatinib-based induction therapy have been explored for elderly patients. With relatively minimal use of imatinib (600 mg/day for three blocks of 60 days) alternating with chemotherapy, a significant improvement in the 1-year survival was observed compared with historical controls.149

Similar results were reported with continuous administration of imatinib (800 mg) only combined with prednisone.146 In a randomized study comparing induction therapy with single-agent imatinib with standard induction chemotherapy,147 response rate was better with single-agent imatinib (96% versus 50%). Achievement of molecular remission was associated with longer DFS. Unfortunately, imatinib resistance developed rapidly and was quickly followed by disease progression. Disease recurrence was related with a high rate of ABL mutations in the tyrosine kinase domain.152

Allogeneic SCT from a sibling donor remains the treatment of choice for postremission in younger adults with Ph+ ALL.155 RIC with fludarabine and 2Gy of TBI was associated with significantly reduced mortality.156 Regular and quantitative BCR-ABL monitoring is strictly necessary if an expectant policy is to be followed.

### Treatment of Burkitt’s lymphoma/leukemia

Accounting for 1% to 3% of all cases of ALL, Burkitt cell ALL is characterized by the morphology of blast cells, the presence of monoclonal surface immunoglobulins, and by chromosomal translocations [t(8;14)(q24;q32), t(2;8) (p12;q24) or t(8;22)(q24;q11)] that lead to rearrangements of the protooncogene c-myc, located at the band 8q24. Burkitt cell ALL prognosis had long been regarded as uniformly poor, because of frequent CNS involvement and early relapses. Conventional ALL treatments combining vincristine, prednisone, an anthracycline, L-asparaginase and intrathecal injections of methotrexate only gave 30% to 50% of CR rates, with most patients subsequently exhibiting CNS relapse. Over the past 15 years, survival has improved with the use of aggressive protocols including intensive induction and early CNS disease treatment. Introduction of fractionated high doses of cyclophosphamide (or ifosfamide), intermediate or high-dose methotrexate and cytarabine, and an epidophyllotoxin (VP16 or VM26) in addition to an anthracycline and vincristine yielded improvements in the outcome of the disease. A 1-week prephase (generally combining cyclophosphamide, vincristine and prednisone) was usually started before high-dose chemotherapy in order to reduce the risk of tumor lysis syndrome. Concomitantly, the poor outcome of Burkitt cell ALL patients with CNS involvement led to approaches using intensification of CNS

<table>
<thead>
<tr>
<th>Reference</th>
<th>Pts</th>
<th>Age</th>
<th>Treatment</th>
<th>CR</th>
<th>Mol CR</th>
<th>OS</th>
<th>DFS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas et al143</td>
<td>11</td>
<td>&gt;15</td>
<td>Chemotherapy + imatinib</td>
<td>100%</td>
<td>27%</td>
<td>75% (2 y)</td>
<td></td>
</tr>
<tr>
<td>Lee et al45</td>
<td>29</td>
<td>&lt;56</td>
<td>Chemotherapy + imatinib</td>
<td>89%</td>
<td>7%</td>
<td>78% (3 y)</td>
<td></td>
</tr>
<tr>
<td>Yanada et al144</td>
<td>80</td>
<td>&lt;65</td>
<td>Chemotherapy + imatinib</td>
<td>96%</td>
<td>71%</td>
<td>76% (1 y)</td>
<td>60% (1 y)</td>
</tr>
<tr>
<td>Wassmann et al148</td>
<td>92</td>
<td>&lt;66</td>
<td>Chemotherapy + imatinib A or S</td>
<td>95%</td>
<td>19%A</td>
<td>72%A</td>
<td>65%A</td>
</tr>
<tr>
<td>Delanoy et al149</td>
<td>30</td>
<td>&gt;54</td>
<td>Chemotherapy + imatinib in consolidation</td>
<td>96%</td>
<td>62%</td>
<td>65% (18 m)</td>
<td>51% (18 m)</td>
</tr>
<tr>
<td>De Labarthe et al150</td>
<td>45</td>
<td>&lt;55</td>
<td>Chemotherapy + imatinib in induction or consolidation</td>
<td>100%</td>
<td>74%</td>
<td>66% (1 y)</td>
<td>58% (1 y)</td>
</tr>
<tr>
<td>Vignetti et al146</td>
<td>30</td>
<td>&gt;60</td>
<td>Imatinib + steroids</td>
<td>96%</td>
<td>43%</td>
<td>61% (1 y)</td>
<td>51% (18 m)</td>
</tr>
<tr>
<td>Ottmann et al147</td>
<td>28</td>
<td>&gt;54</td>
<td>Imatinib then imatinib + chemotherapy</td>
<td>91%</td>
<td>23%</td>
<td>75% (2 y)</td>
<td></td>
</tr>
<tr>
<td>Fielding et al151</td>
<td>89 A</td>
<td></td>
<td>Chemotherapy + imatinib A or S</td>
<td>91%</td>
<td>23%</td>
<td>57% (18 m)</td>
<td>29% (18 m)</td>
</tr>
</tbody>
</table>

Abbreviations: Pts, patients; m, months; A, alternating; S, simultaneous; Mol CR, molecular remission; y, year.
therapy combining high-dose methotrexate (5 to 8 g/m²) and more intrathecal injections, followed by consolidation with etoposide and high-dose cytarabine, and cranial irradiation. CR rates ranged from 60% to 100% and long-term DFS between 50% and 88%.157–161 Recently, rituximab (anti-CD20) has been combined with Burkitt-tailored chemotherapy. Preliminary results show a high response rate.161

Emerging therapy options
Despite continuous progress in curing ALL, novel approaches need to be incorporated into salvage regimens as well as into front-line therapy for high-risk patients. Measurement of minimal residual disease (MRD) has significantly improved risk stratification and helped guide the intensification of therapy. Efforts at improving drug delivery are ongoing and new formulations of existing chemotherapeutic agents have been proposed. Asparaginase is the best example of improvement of an existing formulation of an active agent. Modified versions of L-asparaginase, such as asparaginase from other sources, pegylated formulations, and asparaginase loaded into erythrocytes have been recently proposed as therapeutic alternatives to native L-asparaginase. Polyethylene glycol-conjugated L-asparaginase (PEG-asparaginase) has decreased immunogenicity and a five fold longer half-life, allowing one dose to be substituted for several doses of the native product.162

Monoclonal antibodies (MoAbs) against leukemia-associated antigens and novel molecular therapeutic agents have also been added to certain ALL regimens. Among new formulations of existing chemotherapeutic agents, liposomal cytarabine is a formulation of cytarabine encapsulated into multivesicular lipid-based particles. Cytotoxic levels of cytarabine are maintained for as long as 2 weeks in cerebrospinal fluid after intrathecal administration, compared to less than 24 hours following intrathecal administration of the free cytarabine.163 The use of liposomal anthracyclines has been limited to a Phase I liposomal daunomycin study in relapsed patients, and in combination with standard chemotherapy in elderly patients.164 The clinical benefit of intensive weekly liposomal vincristine in combination with dexamethasone is also being investigated.165

Philadelphia chromosome-negative B cell-lineage ALL
ALL blast cells express a variety of lineage-specific antigens, which are used for the diagnosis and definition of immunological subtypes. Surface and intracellular antigens may also serve as targets for treatment with MoAbs. MoAbs can be administered in several forms: unconjugated form; conjugated to immunotoxins or chemotherapeutic agents, which are carried to the target cell by the antibody; conjugated to radioactive molecules which deliver radiation selectively to malignant cells; as bispecific antibodies, which may reach additional specificity since they are directed at two target antigens; or as direct effector cells to the malignant target. The activity of antibodies depends on the degree of antigen expression on the cell surface. A prerequisite for MoAb therapy was generally the presence of the target antigen on at least 30% of the leukemic blasts. Most experience is available for MoAbs directed against B lineage cells such as anti-CD20, anti-CD19 and anti-CD22. The anti-CD20 MoAbs rituximab added to HyperCVAD regimen has been shown to improve survival of patients with CD20+ ALL.166

The 3-year OS was 75% in the rituximab arm compared with 47% in the control arm. Rituximab is most commonly administered as a 375 mg/m² weekly infusion for 4 to 6 weeks, although alternative schedules have been explored. A fully human anti-CD20 MoAb, ofatumumab, has demonstrated a higher binding affinity and stronger complement-dependent cytotoxicity in comparison to rituximab.167 Epratuzumab (anti-CD22) and its combination with rituximab are currently being evaluated. Blinatumomab, a bispecific anti-CD3 and anti-CD19 monoclonal antibody, is highly effective at time of molecular relapse168 and will be evaluated in first-line therapy. Experience with the humanized anti-CD52, alemtuzumab, in ALL has been anecdotal and consist mostly of reduction of blasts, prolonged pancytopenia with increased risk of opportunistic infections.169

Clofarabine, an adenosine analog, has demonstrated significant single-agent activity in heavily pretreated patients with ALL. Responses were observed in patients with either B-lineage ALL or T-lineage ALL.170 Because clofarabine inhibits both DNA synthesis and repair, several trials are exploring the benefits of combining clofarabine with DNA damaging agents, such as cyclophosphamide or etoposide.171,172 Clofarabine has also been administered in combination with cytarabine, based on the ability of clofarabine to potentiate cytarabine triphosphate accumulation in leukemic blasts.173 Other potential new agents are forodesine, FLT3 inhibitors, proteasome inhibitors, and mammalian target of rapamycin mTOR inhibitors.

T cell-lineage ALL
T-lineage ALL are distributed into different subtypes according to maturation stage: thymic (56%), early-T (23%), and mature-T (21%). A correlation has been reported between maturation stage and outcome with the best outcome for thymic T-cell ALL (OS: 60% to 70%) compared to early- (33%) and mature-T phenotypes (22%).174,175
Several new options for targeted therapy for T-lineage ALL are forthcoming. Nucleoside analogs represent a large group of agents under investigation in T-cell lineage ALL. The purine analog nelarabine is a water-soluble prodrug of 9-β-D-arabinofuranosylguanine (ara-G), a deoxyguanosine derivative that is resistant to the clivage by purine nucleoside phosphorylase (PNP). T cells are more sensitive to PNP inhibition than B cells because of their inherently higher kinase and lower nucleotidase levels, favoring phosphorylation of deoxyguanosine. In an adult trial, 26 patients received nelarabine on an alternate day schedule (days 1, 3, and 5) at 1500 mg/m² per day, and 31% of them achieved CR. Nelarabine could soon be integrated in front-line therapy. Forodesine, a PNP inhibitor, is most effective when administered in a continuous daily schedule and may therefore be useful during maintenance therapy.

Members of the NOTCH family have been recently described to play a critical role in T cell development and their constitutive activation has been linked to T-cell lineage leukemia. γ-secretase, which participates in the release of the NOTCH1 intracellular domain before it translocates to the nucleus, is a potential therapeutic target. Small molecule γ-secretase inhibitors are being intensively studied.

The NUP214-ABL1 fusion is mainly present in T-lineage ALL expressing HOX11 or HOX11L2. Recently, it appears that imatinib mesylate is potentially efficient in these cases. Purine nucleoside phosphorylase (PNP) is a purine-metabolizing enzyme that catalyzes the phosphorolysis of purine nucleosides. The unique sensitivity of T-cells to PNP deficiency is attributed to a relatively high level of kinase and low level of nucleotidase activity. Specific inhibitors of PNP are currently in development.

mTOR is a large polypeptide kinase that acts as a nutrient sensor and regulator of translation. mTOR regulates the translation of a specific subset of mRNA transcripts that encode proteins involved in regulating the G1 to S phase transition. Rapamycin and the second generation mTOR inhibitors (temsirolimus, everolimus, deforolimus) are able to disrupt the function of mTOR and downstream signaling pathways contributing to cellular proliferation. They form potentially synergistic combinations with doxorubicin and methotrexate.

Philadelphia chromosome-positive ALL

BCR-ABL has tyrosine kinase activity and participates in intracellular signal transduction pathways. Because mutations that inactivate the kinase function result in a transformation-defective protein, it was predicted that small molecular inhibitors of the kinase activity would be highly effective antileukemic agents. New molecular therapeutic strategies with imatinib and other new kinase inhibitors (dasatinib, nilotinib) are being explored in Philadelphia chromosome/BCR-ABL positive ALL.

New strategies, using second generation TKIs, are being developed to overcome resistance to imatinib. Dasatinib, offering simultaneous inhibition of both tyrosine and SRC kinases, may hold more promise in terms of long-term benefit than imatinib, which offers tyrosine kinase inhibition alone. A recent Phase II study combining the hyperCVAD regimen with dasatinib (50 mg BID) for the first 14 days of each cycle showed CR achievement in 93% of newly diagnosed Ph+ ALL, with molecular remissions observed even after the first cycle. In a series combining dasatinib (70 mg BID) with only steroids, CR was achieved in all cases with a very marked clearance of blasts already at day 22. Nilotinib as monotherapy also appeared to have promising activity and a favorable safety profile. Its use in combination with chemotherapy is currently tested. Even 20-fold more potent BCR-ABL inhibition with nilotinib did not induce apoptosis of quiescent CD34+ cells nor did inhibition with a dual SRC-ABL kinase inhibitor.

The appearance of mutations which are most probably but not exclusively related to resistance led to the avoidance of induction drugs such as anthracyclines or alkylating agents, which can cause mutational resistance; and the preference for methotrexate, cytarabine, and asparaginase. Such a trial in older adult patients led to high CR rate and improved survival.

Resistance attributable to kinase domain mutations can lead to relapse despite the development of second-generation compounds, including dasatinib and nilotinib. Despite these therapeutic options, the cross-resistant BCR-ABL T315I mutation remains a major clinical challenge. The first evaluations of AP24534 (ponatinib) characterize this drug as a potent multitargeted kinase inhibitor active against T315I and all other BCR-ABL mutants. AP24534 could be the next treatment of choice in hematological malignancies with Ph+ chromosome, particularly Ph+ ALL known for its frequent occurrence of T315I mutation. However, its potential action on LSCs is still unknown.

**Impact on management strategies and patient care**

**Acute myeloid leukemia**

**Better classification of AML**

AML is a heterogeneous disease with large differences in prognosis. Advances in supportive care and better characterization of disease subsets through cytogenetics and molecular
analysis have led to significant successes in specific subsets of patients such as those with APL and CBF leukemias. In APL, the past two decades have witnessed remarkable advances that transformed this once rapidly fatal disease into the most curable acute leukemia. The introduction of ATRA in the therapy of APL represents the first paradigm of molecularly targeted treatment in human cancer. The more recent introduction of arsenic trioxide has marked an additional milestone in APL treatment. In CBF leukemias, high-dose cytarabine-based regimens now results in cure rates of 60% to 80%.45,46

Although there is consensus on classification and prognostic value of favorable and unfavorable cytogenetics, molecular factors have been identified to refine the risk profile of patients with AML. On the basis of a literature review and expert consensus, European Leukemia Net (ELN) recommendations on diagnosis and management of AML have recently proposed a subdivision of the intermediate risk group. Patients with normal karyotype and either NPM1 or CEBPα genes and absent FLT3-ITD mutation were assigned to the favorable risk group. All other patients with a normal karyotype were classified as intermediate-I. Patients with cytogenetic aberrations not classified as favorable or unfavorable form the intermediate-II group (Table 5).47 In younger adults with AML, the ELN classification seems to be the best available framework for prognostic estimations.190

Table 5 Standardized reporting for correlation of cytogenetic and molecular genetic data in AML with clinical data according to the ELN guideline47

<table>
<thead>
<tr>
<th>ELN genetic risk group</th>
<th>Subsets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Favorable</td>
<td>t(8;21)(q22;q22); RUNX1-RUNX1T1</td>
</tr>
<tr>
<td></td>
<td>inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11</td>
</tr>
<tr>
<td></td>
<td>Mutated NPM1 without FLT3-ITD (normal karyotype)</td>
</tr>
<tr>
<td></td>
<td>Mutated CEBPα (normal karyotype)</td>
</tr>
<tr>
<td>Intermediate-I</td>
<td>Mutated NPM1 and FLT3-ITD (normal karyotype)</td>
</tr>
<tr>
<td></td>
<td>Wild-type NPM1 and FLT3-ITD (normal karyotype)</td>
</tr>
<tr>
<td></td>
<td>Wild-type NPM1 without FLT3-ITD (normal karyotype)</td>
</tr>
<tr>
<td>Intermediate-II</td>
<td>t(9;11)(p22;q23); MLLT3-MLL</td>
</tr>
<tr>
<td></td>
<td>Cytogenetic abnormalities not classified as favorable or adverse</td>
</tr>
<tr>
<td>Adverse</td>
<td>inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1</td>
</tr>
<tr>
<td></td>
<td>t(6;9)(p23;q34); DEK-NUP214</td>
</tr>
<tr>
<td></td>
<td>t(11)(q23); MLL rearranged</td>
</tr>
<tr>
<td></td>
<td>−5 or del(5q); −7; abnl(17p); complex karyotype</td>
</tr>
</tbody>
</table>

Demonstration of MRD by multicolor flow cytometry is also correlated with inferior outcomes.192 Postremission assessments of MRD are rapidly becoming part of the standard of care in AML, although the frequency and optimal timing of such assessments are still not clear.

Treatment of elderly patients with AML

There is reluctance from both patients and physicians to expose older patients to the toxic effects of standard chemotherapy. The benefit associated with intensive chemotherapy remains largely debated, with an extremely poor outcome, even in patients with favorable cytogenetics. Only one third of elderly patients receive intensive induction chemotherapy.193 A number of risk scores, in which adjusted hazard ratios from multivariate analyses were used to assign weighted risk points to the identified prognostic factors, have been developed for identifying patients likely to benefit from the traditional induction regimens.194-198 Several indices have also been created to measure the influence of comorbidities on the outcome of treatment, and proposed as a counseling and selection tool. Theoretically, the decision regarding the best strategy in elderly patients should be based on the expected outcomes using these risk scores and biological characteristics. Although (in contrast with observations in younger adults) a recent study suggested that a delay in treatment initiation in older patients was feasible and did not affect survival,199 do we have time to evaluate patients for these predictors? Sophisticated scoring systems appear now very questionable and not prospectively applicable in daily clinical practice. Models based on risk scores did not take into account the entire population of elderly AML patients, because only patients fit for intensive chemotherapy would benefit from this stratification. Despite the establishment of prognostic indexes leading theoretically to a practical framework for therapeutic decision making, the choice between intensive chemotherapy or new investigational drugs in this patient population remains under the local physician’s decision, generally based more on the ‘sens clinique’ than on mathematical models.200 Even if age, white blood cell count and LDH level are immediately available, molecular biology, and even cytogenetics and immunology are not always available at the time of treatment decision. After referring first to the performance status and/or the presence of potential comorbidities for eliminating patients who might receive only supportive care, physician’s therapeutic decision making generally takes into account the hematological presentation of AML referring to the proliferative and/or invasive characteristics of leukemia. New therapeutic agents should
modify our vision of treating older adults. Hypomethylating agents usually proposed for so-called ‘unfit’ patients yielded interesting results recently in patients usually oriented to intensive chemotherapy (Table 6), with less toxicity, reduced time spent in hospital, and efficacy correlated with reexpression of silenced genes. 81,83 Achievement of remission did not appear to be a precondition for longer survival, as well as the presence of multiple adverse prognostic factors.

**Acute lymphoblastic leukemia**

**Monitoring of MRD**

The optimal type and duration of postremission therapy, the value of further intensifications, and the optimal selection and timing of allogeneic SCT are still debated. Identifying reliable tools for proper patient selection is becoming crucial. The application of new genome-wide screening techniques, such as microarray-based gene expression studies and array-comparative genomic hybridization (array-CGH) studies, have led to the discovery of new genetic abnormalities for which the exact functional role remains to be investigated. Pharmacogenomics has great potential to improve the use of anti-leukemic agents to reduce toxicity and enhance efficacy by guiding optimal treatment selection, dose individualization, and new drug discovery. 201 Monitoring of MRD after induction and during consolidation therapy have become powerful predictors of disease recurrence and is used to stratify patients according to risk. 202 MRD is evaluable using either multichannel flow cytometry or the real-time quantitative polymerase chain reaction (RQ-PCR). The speed of MRD eradication or the persistence of MRD over time is also predictive. 203 MRD monitoring is important in the setting of allogeneic SCT in which high levels before transplant or persistent residual disease after transplant confer a poorer outcome.

**Treatment of elderly patients with ALL**

Elderly patients have a worse prognosis than younger adults with ALL. Their long-term survival probability is generally under 20%. 204 Intensifying chemotherapy reduces the incidence of leukemia resistance, but increases the incidence of death in CR from myelosuppression-related complications. The development of moderate dose intensity consolidation, like those reported by the European Working Group for Adult ALL showing 85% of CR and a 61% 1-year survival, are warranted. 205 Targeted drugs in combination with moderately intensified chemotherapy may also be successful. Cure can rarely be achieved in patients older than 70 years, for which control of leukemic cells and maintenance of an acceptable quality of life are the major goals of management.

**Treatment of adolescents and young adults**

Studies of ALL in AYAs demonstrated improved survival for those who were treated by pediatric groups. 124–128 The 5- to 6-year EFS rate for AYAs treated with pediatric regimens ranges from 65% to 70%. Reasons explaining this difference include: differences in protocol designs with higher doses of drugs, early and more frequent CNS prophylaxis, and dexamethasone instead of prednisone; biological differences; different practice patterns; and social factors such as support systems and compliance. Sequential measurements of MRD in AYAs with standard-risk ALL treated with pediatric-based schedules will probably provide help in selecting the minority of patients who should be treated with high-risk ALL approaches including allogeneic SCT in first CR. Recently, a pediatric-inspired therapy program for adults has been published showing results comparing favorably with those reported from previous adult programs. 206 Prospective trials are planned with the possibility of extending the pediatric approach to adults aged up to 40–50 years. 207,208

**Future research directions**

Leukemia is propagated by a subpopulation of leukemia stem cells (LSCs). 209,210 From a clinical perspective, it has been demonstrated that LSCs are substantially more resistant to standard forms of chemotherapy than bulk leukemia populations. Thus, elucidating the specific molecular and cellular properties that mediate LSCs survival is an extremely
important step toward therapeutic success in leukemia. Novel therapies should target both leukemic cells and cells in their surrounding microenvironment. The therapeutic strategies designed to target LSCs within their surrounding microenvironment include adhesion molecule and cytokine antagonists as well as inhibitors of intracellular prosurvival and self-renewal pathways. Upregulation of the prosurvival Bcl-2 and Mcl-1 pathways is a frequent characteristic in leukemic cells in contact with the microenvironment. This could be targeted by drugs such as BH3 mimetics (Bcl-2, ABT-737) or kinase/Cdk inhibitors (Mcl-1, MEK inhibitors). Disruption of migratory and adhesion signals represents an attractive strategy of blocking LSC homing and/or sensitizing leukemic cells to chemotherapy. Targeting CXCR4 has been shown to be efficacious through recruitment of leukemic cells out of their protective microenvironment.\textsuperscript{211,212} The use of neutralizing VLA-4 antibody and inhibitors of VLA-4/VCAM-1 interactions are currently explored in leukemia.\textsuperscript{213} Specific antibodies against CD44, CD123, and CD47 have been reported to reduce the growth of LSCs in leukemias.\textsuperscript{213} Targeting angiogenesis has also been developed for influencing the relationship between LSCs and their microenvironment. The anti-VEGF monoclonal antibody bevacizumab combined with chemotherapy has been demonstrated to improve overall response in a Phase II study.\textsuperscript{86} These approaches may selectively eradicate LSCs without adversely affecting normal stem cells.\textsuperscript{217}

Conclusion

Long-term survival for adult leukemias have improved largely through more intensive use of conventional cytotoxic agents and the development of new conditioning regimens and procedures for transplantation evaluated in the context of large, randomized clinical trials. Clinical factors, genetic features, and initial response to therapy are used in concert to define risk-adapted treatment for all patients. Major recent breakthroughs in therapies have been furthered by important laboratory discoveries. Advances in genomics have also led to opportunities for the application of novel targeted treatments. Several subsets of AML have benefited from recent discoveries. In CBF leukemias, high-dose cytarabine-based regimens have significantly improved outcomes. Molecular studies have also identified patients for whom resistance may be circumvented through the addition of tyrosine kinase inhibitors targeting mutated c-Kit. In APL, non chemotherapy strategies using ATRA and arsenic trioxide are currently in development. Several molecular aberrations have been described and have important prognostic implications in cytotologically normal AML, yielding to a risk-adapted therapeutic strategy. In ALL, combining chemotherapy with targeted therapies has significantly increased the survival rates in Ph+ ALL and in Burkitt lymphoma/leukemia, and rituximab has shown a benefit in the subset of CD20\textsuperscript{+} B-lineage ALL. Improvements in preparative regimens and supportive care measures have also facilitated the expanded application of allogeneic SCT. Future treatment directions aim to improve therapeutic targeting of LSCs. In this setting, new regimens must take into consideration the quiescent cell cycle status of LSCs and therapies must either be capable of killing quiescent cells or activating LSCs cell cycle. Other therapeutic approaches must target cell properties that are most consistently aberrant in LSCs.

Disclosure

The author reports no conflicts of interest in this work.

References


54. Büchner T, Berdel WE, Schoch C, et al. Late events in AML. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukaemia. J Clin Oncol. 2006;24:2480–2489.


